News | May 27, 2025
Akums reports Q4 FY25 with 12.4% revenue growth
Akums invested Rs. 272 crore in capital expenditure during FY25
Akums invested Rs. 272 crore in capital expenditure during FY25
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Subscribe To Our Newsletter & Stay Updated
